 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
 |
|
|
|
|
|
Neuroprotective therapy: Neuroprotective therapy:: There are several different classes of agents under active investigation which are thought to provide neuronal protection. In stroke, the disruption of blood flow results in numerous cellular and biochemical events. The ischemia causes energy failure and depolarization with release of neurotransmitters, influx of intracellular calcium, and release of free radicals. With better understanding of the mechanisms of neuronal damage and death new cytoprotective therapies are being studied. Many of these agents have demonstrated reduction of stroke volume in animal models of stroke and are undergoing clinical trials. Several of these agents have shown promise for the treatment of traumatic brain injury and neurodegenerative diseases such as amyotrophic lateral sclerosis and Huntington*s disease. Agents currently under study include excitatory antagonists, free radical scavengers, gangliosides, and leukocyte inhibitiors; unfortunately all of these agents remain experimental with no defined role in acute stroke management. |
|||
|
|
|||